SPA
ABUS icon

Sherbrooke Park Advisers’s Arbutus Biopharma ABUS Stock Holding History

Sherbrooke Park Advisers’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$135K Sell
27,989
-9,084
-25% -$40.8K 0.35% 113
2025
Q3 		$168K Buy
37,073
+15,439
+71% +$56.7K 0.08% 404
2025
Q2 		$66.8K Buy
+21,634
New +$71.8K 0.03% 486
2024
Q4 		– Sell
-67,455
Closed -$260K – 721
2024
Q3 		$260K Buy
67,455
+25,841
+62% +$99.1K 0.06% 636
2024
Q2 		$129K Buy
+41,614
New +$125K 0.02% 815

Other funds holding ABUS

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
WCM
Whitefort Capital Management New York $339M AUM 52.48% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Sherbrooke Park Advisers's ABUS Position: Q4 2025 in Review

Sherbrooke Park Advisers reduced its Arbutus Biopharma (ABUS) stake by 25% in Q4 2025, selling an estimated $40.8K and leaving 27,989 shares worth $135K. The position accounts for 0.35% of the portfolio, ranked #113.

Sherbrooke Park Advisers first reported a position in ABUS in Q2 2024 and has held it in 5 quarters since. The position peaked at $260K in Q3 2024. 172 funds tracked by Wall St. Rank hold ABUS as of Q4 2025.

  • Sherbrooke Park Advisers held 27,989 shares of Arbutus Biopharma worth $135K as of Q4 2025.
  • Sherbrooke Park Advisers sold 9,084 Arbutus Biopharma shares in Q4 2025, an estimated $40.8K.
  • Arbutus Biopharma made up 0.35% of Sherbrooke Park Advisers's portfolio in Q4 2025, its #113 holding.
  • Sherbrooke Park Advisers first reported a position in Arbutus Biopharma in Q2 2024 and has held it in 5 quarters since.
  • Sherbrooke Park Advisers's Arbutus Biopharma position peaked at $260K in Q3 2024.
  • 172 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q4 2025.

Based on Sherbrooke Park Advisers's 13F filing for Q4 2025, filed 17 Feb 2026.